The in vitro inhibitory effects of quinolones on the bacterial DNA gyrase of Escherichia coli KL-16 and topoisomerase II of fetal calf thymus were compared. All the quinolones tested required higher concentrations to inhibit the topoisomerase II than to inhibit the DNA gyrase, and no correlation existed among their inhibitory activities against both enzymes. However, there was a large difference among the quinolones in their selectivities between the bacterial enzyme and its eucaryotic counterpart. The selectivity of ofloxacin was highest, and the selectivities of CI-934 and nalidixic acid were lowest.
The in vitro inhibitory effects of quinolones on the bacterial DNA gyrase of Escherichia coli KL-16 and topoisomerase II of fetal calf thymus were compared. All the quinolones tested required higher concentrations to inhibit the topoisomerase II than to inhibit the DNA gyrase, and no correlation existed among their inhibitory activities against both enzymes. However, there was a large difference among the quinolones in their selectivities between the bacterial enzyme and its eucaryotic counterpart. The selectivity of ofloxacin was highest, and the selectivities of CI-934 and nalidixic acid were lowest.
DNA topoisomerases are a class of enzymes that alter the topology of DNA (3, 18, 28) . These enzymes catalyze the reactions called supercoiling, relaxing, knotting, or catenating. Among these enzymes, bacterial topoisomerase II (DNA gyrase) has been purified from various bacterial species such as Escherichia coli, Pseudomonas aeruginosa, Citrobacter freundii, and Bacteroides fragilis and has been verified to be a major target of quinolones (1, 15, 22, 23) . Eucaryotic topoisomerase II also has been purified from various sources (2, 4, 8, 9, 19, 20, 25) , including bovine calf thymus. Hussy et al. (13) have reported that quinolones such as ciprofloxacin, norfloxacin, and ofloxacin interfere slightly with the function of mammalian topoisomerase II as well. We purified DNA gyrase and mammalian topoisomerase II from E. coli and fetal calf thymus, respectively, and examined the selectivities of various quinolones in terms of their inhibitory effects on both enzymes by the use of plasmid DNA as substrates.
Ofloxacin (24) , ciprofloxacin (29) , enoxacin (16) , fleroxacin (10), CI-934 (12), T-3262 (5), lomefloxacin (11) , and nalidixic acid were synthesized in our laboratory. All other agents were purchased from their respective manufacturers and were at least of analytical grade. Supercoiled pBR322 plasmid DNA was prepared by the cesium chloride density gradient method (17) and was relaxed by topoisomerase I (Bethesda Research Laboratories, Inc., Gaithersburg, Md.). The A and B subunits of DNA gyrase were purified separately from E. coli KL-16 by using novobiocin-epoxy-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, N.J.) and heparin-Sepharose CL-6B (Pharmacia) column chromatographies, as described previously (6, 26) . Topoisomerase II was purified from the isolated nuclei of calf thymus by using BioRex 70 ion-exchange (Bio-Rad Laboratories, Richmond, Calif.), hydroxyapatite (Bio-Rad), Affigel Blue (Bio-Rad), and double-stranded DNA cellulose (Sigma Chemical Co., St. Louis, Mo.) column chromatographies by the method of Halligan et al. (9) .
The activity of the reconstituted DNA gyrase in the presence and absence of quinolones was determined by previously described methods (6, 7) . One unit of enzyme activity was defined as the amount that brought 50% of relaxed pBR322 plasmid DNA to the supercoiled form, as detected following electrophoresis in agarose. The reaction mixture (20 , Purified subunits A and B of DNA gyrase and topoisomerase II were verified to be almost homogeneous on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with specific activities of 104, 104, and 106 U/mg of protein, respectively. The supercoiling activity of the reconstituted DNA gyrase against relaxed pBR322 required ATP. In the absence of ATP, no supercoiling activity was observed. The optimal concentration of ATP ranged from 0.39 to 1.56 mM. The enzyme also needed Mg2+ to supercoil pBR322, with the optimal concentrations ranging from 0.5 to 50 mM. The topoisomerase II also exhibited ATP-and Mg2+-dependent relaxing activities, with the optimal concentrations ranging from 0.1 to 6.25 mM and 3.13 to 12.5 mM, respectively. In the absence of ATP, no relaxing activity was observed, indicating that there was no contamination of topoisomerase I in the preparations.
The inhibitory effects of the tested quinolones on both DNA gyrase and topoisomerase II are shown in floxacin, T-3262, lomefloxacin, enoxacin, CI-934, and nalidixic acid for the DNA gyrase were 0.76, 0.52, 0.13, 0.37, 0.78, 1.72, 3.55, and 23.0 ,ug/ml, respectively. These values correlated roughly with their antibacterial activities against E. coli KL-16. The ID50s for topoisomerase II, on the other hand, varied within 2 orders of magnitude, between 64 and 1,840 ,ug/ml, for the various compounds. The potency of inhibition was lowest for ofloxacin, followed by fleroxacin, nalidixic acid, lomefloxacin, T-3262, ciprofloxacin, enoxacin, and CI-934 in the order of increasing potency, indicating that there was no correlation between their inhibitory activities against the target bacterial enzyme and its mammalian counterpart, topoisomerase II.
Eucaryotic topoisomerase II is known as an essential enzyme for cell growth (3). The bacterial DNA gyrases, which are assumed to be the target of quinolones (1, 15, 22, 23) , belong to the type II topoisomerase and exhibit a function similar to that of eucaryotic topoisomerase II. Since the inhibition of eucaryotic topoisomerase II would be an undesirable side effect of antibacterial chemotherapy with quinolones, there have been several studies on the inhibitory effects of quinolones against the enzyme (13, 14) . Among them, Hussy et al. (13) have demonstrated that eucaryotic topoisomerase II is much less sensitive to inhibition by norfloxacin, ofloxacin, and ciprofloxacin than is bacterial DNA gyrase. We also purified both enzymes and investigated the inhibitory effects of quinolones, including those that have been developed recently, against these enzymes by use of the same amount of pBR322 as substrates. The properties of our preparations were in accordance with data reported earlier (9, 27) in terms of ATP and Mg2" dependencies. Furthermore, our ID50s of ciprofloxacin and ofloxacin against the eucaryotic enzyme were comparable to those reported by Hussy et al. (13) . Although all the quinolones tested required higher concentrations to inhibit the topoisomerase II than to inhibit the DNA gyrase, without exception, there was a large difference among the quinolones in their selectivities between the bacterial and mammalian enzymes. The selectivities were high for ofloxacin, ciprofloxacin, and fleroxacin; moderate for lomefloxacin and T-3262; and poor for enoxacin, CI-934, and nalidixic acid (Table 1) . No correlation existed between the inhibitory activities of these quinolones against both enzymes. The cytotoxicities of ofloxacin and ciprofloxacin against cultured lymphoblasts have been reported to be approximately 100 to 1,000 times lower than those of DNA cross-linking agents such as cis-platinum, melphalan, and mitomycin C (13). Furthermore, it has been shown (21) that ofloxacin and pefloxacin are unable to inhibit human myelopoiesis in vitro. However, the cytotoxicities of quinolones in relation to their inhibitory activities against enzymes that are essential for DNA replication, including topoisomerase II, need to be investigated further.
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